Heart failure (HF) is one of the leading causes of death among chronic diseases worldwide. In recent years, there have been several breakthroughs in its pharmaceutical treatment. Recent clinical trials have demonstrated that combination therapy can significantly improve the survival rate and quality of life of heart failure patients. However, controversies surrounding the safety of these combination treatments still persist in academic and clinical circles.
What is Combination Therapy for Heart Failure?
Combination therapy refers to the simultaneous use of two or more medications in the treatment of heart failure, aiming to achieve synergistic effects through different mechanisms and enhance therapeutic outcomes. Common combination therapy regimens include:
1.SGLT2 Inhibitors (e.g., dapagliflozin): Reduce blood glucose and cardiac workload by inhibiting renal glucose reabsorption.
2.GLP-1 Receptor Agonists: Improve insulin secretion and myocardial metabolism, offering both glucose-lowering and cardioprotective effects.
3.Angiotensin Receptor/Neprilysin Inhibitors (ARNIs) (e.g., sacubitril/valsartan): Regulate cardiac and vascular pressure load, recognized as the first-line therapy for heart failure.
4.Dual SGLT1/SGLT2 Inhibitors (e.g., sotagliflozin): A new class of medication that regulates both intestinal and renal metabolism.
Remarkable Efficacy, Transforming the Landscape of Heart Failure Treatment
In clinical trials involving over 10,000 patients, sotagliflozin (Inpefa) reduced the risk of myocardial infarction, stroke, and cardiovascular death in heart failure patients by 23%. At the same time, the combination use of SGLT2 inhibitors and GLP-1 receptor agonists has shown excellent results in reducing hospitalization and mortality rates among heart failure patients with comorbid diabetes or chronic kidney disease.
These combination therapies not only effectively alleviate patient symptoms but, more importantly, reduce the long-term risk of cardiovascular events, commented the American College of Cardiology (ACC).
Safety Concerns: Hypotension and Renal Function Risks Not to Be Overlooked
Despite the impressive efficacy, these therapies have raised safety concerns. Studies indicate that certain populations, including the elderly, those with low blood pressure, or patients with impaired renal function, may experience risks such as hypotension, dehydration, and acute kidney injury when receiving SGLT2 inhibitor combination therapy.
Future Trend: Precision Medicine and Personalized Risk Management
Looking ahead, heart failure treatment is expected to move towards personalized precision therapy, where treatment strategies are tailored based on individual characteristics such as age, renal function, and blood pressure levels. For high-risk patients, stricter monitoring and dosage adjustments will be essential to ensure a balance between efficacy and safety.
Combination therapy is gradually reshaping the landscape of heart failure treatment. However, the ongoing safety concerns serve as a reminder that every advancement in medicine must be accompanied by robust risk management strategies.
